Non-Alcoholic Fatty Liver DiseaseSymptoms, Doctors, Treatments, Advances & More
Learn About Non-Alcoholic Fatty Liver Disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition that is characterized by a buildup of fat in the liver, which can lead to liver damage. The liver is part of the digestive system, and it helps break down food, store energy, and remove waste products. If more than 5 percent of the liver contains fat, the liver is considered to be fatty (steatotic).
The specific causes of MASLD are unclear, although this condition is likely a result of both environmental factors and changes in several genes. Genetic changes that increase the risk of disease are called pathogenic variants.
Common conditions include: Nonalcoholic Steatohepatitis (NASH)
MASLD occurs in about 25 percent adults and 7 to 14 percent of children worldwide. It is the most common chronic liver disorder in Western countries, including the United States, and its prevalence is increasing along with the rising prevalence of obesity. It is estimated that MASLD will affect over half of individuals by 2040.
An increased risk of developing MASLD can be passed down through generations in families, but the inheritance pattern is unknown.
Private Diagnostic Clinic PLLC
Manal Abdelmalek is a Gastroenterologist practicing medicine in Durham, North Carolina. Dr. Abdelmalek is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Cirrhosis, Enlarged Liver, and Liver Transplant. Dr. Abdelmalek is currently accepting new patients.
UChicago Medicine Duchossois Center For Advanced Medicine - Hyde Park
Mary Rinella is a Hepatologist practicing medicine in Chicago, Illinois. Dr. Rinella is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, Cirrhosis, Liver Transplant, and Endoscopy. Dr. Rinella is board certified in Gastroenterology Transplant Hepatology and Practicing Since2002. Dr. Rinella is currently accepting new patients.
UT Southwestern - Digestive Disease Clinic
Lisa Vanwagner is a Gastroenterologist practicing medicine in Dallas, Texas. Dr. Vanwagner is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Liver Failure, Liver Transplant, and Kidney Transplant. Dr. Vanwagner is currently accepting new patients.
Summary: This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Summary: This study is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation phase I clinical trial aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of MWN105 injection in Chinese non-diabetic overweight or obese participants. The study plans to enroll 36 male and female participants. Three dose groups were preset, with 12 particip...
Published Date: April 01, 2026
Published By: National Institutes of Health